Advertisement
Advertisement
Trending on BioPharm International
1
Genmab’s Petosemtamab Plus Pembrolizumab Cuts Risk of Death by 50% in Phase 3 Head and Neck Cancer Trial
2
Adalvo Acquires Enzene’s Romiplostim Biosimilar Program for ITP
3
How Lipid-Based Softgels Protect Oral Peptides from Degradation
4
3SBio and Pfizer’s PD-1×VEGF Bispecific Shows Durable PFS Gains in First-Line NSCLC
5